Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia
NCT00345410
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
345
Enrollment
INDUSTRY
Sponsor class
Conditions
Obesity
Dyslipidemia
Interventions
DRUG:
AVE1625 B
Sponsor
Sanofi